Ovarian cancer kills more women than any other gynecologic cancer precisely because it is almost always diagnosed late — when five-year survival drops below 30%. The central diagnostic problem is not treatment but detection, and a new comprehensive review maps how rapidly evolving biosensor platforms may finally change that calculus for high-risk populations and general screening alike.
The review, published in Clinica Chimica Acta, synthesizes recent progress across three immunosensor modalities — electrochemical, optical, and piezoelectric — each engineered to detect ovarian cancer-associated biomarkers with ultrasensitive precision. While CA-125 remains the most clinically recognized marker, its limited specificity has long frustrated early-stage detection. The platforms assessed here move beyond single-marker reliance by quantifying multi-marker panels that include HE4 and mesothelin alongside CA-125, using nanomaterial scaffolds and microfluidic integration to achieve detection thresholds well below conventional immunoassay limits. Signal amplification strategies further extend sensitivity into the femtomolar range, theoretically enabling detection of tumor-associated proteins before symptoms or imaging anomalies appear.
The broader diagnostic landscape for ovarian cancer has struggled for decades: the PLCO randomized trial demonstrated that CA-125 combined with transvaginal ultrasound did not reduce mortality at population scale, underscoring the urgent need for genuinely superior modalities. Immunosensor platforms represent a fundamentally different approach — moving signal transduction to miniaturized, point-of-care form factors that could enable decentralized or community-level screening. That said, this is a review of laboratory-stage and early translational research. The field has yet to produce large prospective clinical validation studies demonstrating that immunosensor-detected biomarker shifts translate into meaningful survival improvements. Key hurdles include matrix interference in real serum samples, device reproducibility across manufacturing batches, and regulatory pathways for multi-marker panel approval. The work is incremental-to-promising rather than paradigm-shifting, but the convergence of nanotechnology and multiplexed biomarker panels represents a credible path forward that earlier diagnostic technologies lacked.